United States Securities and Exchange Commission Form

Total Page:16

File Type:pdf, Size:1020Kb

United States Securities and Exchange Commission Form Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended February 27, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission File Number 1-5742 RITE AID CORPORATION (Exact name of registrant as specified in its charter) Delaware 23-1614034 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 30 Hunter Lane, Camp Hill, Pennsylvania 17011 (Address of principal executive offices) (Zip Code) Registrant’s telephone number, including area code: (717) 761-2633 Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $1.00 par value RAD New York Stock Exchange Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the registrant is a well known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No ☐ Indicate by check mark if the registrant is not required to file reports pursuant to section 13 or section 15(d) of the Exchange Act. Yes ☐ No ☒ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit such files). Yes ☒ No ☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “Large Accelerated Filer,” “Accelerated Filer,” “Smaller Reporting Company,” and “Emerging Growth Company” in Rule 12b-2 of the Exchange Act. Large Accelerated Filer ☐ Accelerated Filer ☒ Non-Accelerated Filer ☐ Smaller reporting company ☐ Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☒ The aggregate market value of the voting and non-voting common stock of the registrant held by non-affiliates of the registrant based on the closing price at which such stock was sold on the New York Stock Exchange on August 29, 2020 was approximately $737,566,209. For purposes of this calculation, only executive officers and directors are deemed to be affiliates of the registrant. As of April 15, 2021 the registrant had outstanding 55,101,661 shares of common stock, par value $1.00 per share. DOCUMENTS INCORPORATED BY REFERENCE Certain portions of the registrant’s definitive proxy statement pursuant to Regulation 14A of the Securities Exchange Act of 1934 or an amendment to this Annual Report on Form 10-K, to be filed with the Securities and Exchange Commission, are incorporated by reference into Part III of this Annual Report on Form 10-K. Table of Contents TABLE OF CONTENTS Page Cautionary Statement Regarding Forward-Looking Statements 3 PART I ITEM 1. Business 5 ITEM 1A. Risk Factors 20 ITEM 1B. Unresolved Staff Comments 40 ITEM 2. Properties 40 ITEM 3. Legal Proceedings 41 ITEM 4. Mine Safety Disclosures 42 PART II ITEM 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 43 ITEM 6. Selected Financial Data 46 ITEM 7. Management’s Discussion and Analysis of Financial Condition and Results of Continuing Operations 47 ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk 73 ITEM 8. Financial Statements and Supplementary Data 73 ITEM 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 73 ITEM 9A. Controls and Procedures 74 ITEM 9B. Other Information 76 PART III ITEM 10. Directors, Executive Officers and Corporate Governance 77 ITEM 11. Executive Compensation 77 ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 77 ITEM 13. Certain Relationships and Related Transactions, and Director Independence 77 ITEM 14. Principal Accountant Fees and Services 77 PART IV ITEM 15. Exhibits and Financial Statement Schedule 78 ITEM 16. Form 10-K Summary 83 SIGNATURES 84 2 Table of Contents CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This report, as well as our other public filings or public statements, include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by terms and phrases such as “anticipate,” “believe,” “intend,” “estimate,” “expect,” “continue,” “should,” “could,” “may,” “plan,” “project,” “predict,” “will” and similar expressions and include references to assumptions and relate to our future prospects, developments and business strategies. Factors that could cause actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: ● the impact of widespread health developments, including the continued impact of the global coronavirus (“COVID-19”) pandemic, and the responses thereto (such as quarantines, shut downs and other restrictions on travel and commercial, social and other activities), including changing consumer behavior and preferences and the reinstitution of more stringent regulations (including mandatory stay at home orders and the availability, rollout and supply chain of vaccines to treat the virus), which could materially and adversely affect, among other things, the economic, financial and labor markets in which we operate, access to credit, our front-end and pharmaceutical operations, supply chain, associates and executive and administrative personnel. These widespread health developments, or an increase in the number of cases, could also materially and adversely affect our third-party service providers, including suppliers, vendors and business partners, and customers. The COVID-19 pandemic has resulted in recessionary economic conditions which could negatively impact our sales. Any of these developments could result in a material adverse effect on our business, financial conditions and results of operations; ● our ability to successfully implement RxEvolution, attract and retain a sufficient number of our target consumers, integrate acquisitions, our ability to obtain permits required for store remodels, and improve the operating performance of our stores; ● our high level of indebtedness, the ability to refinance such indebtedness on acceptable terms, and our ability to satisfy our obligations and the other covenants contained in our debt agreements; ● the nature, cost and outcome of pending and future litigation, other legal or regulatory proceedings, or governmental investigations, including those related to Opioids, “usual and customary” pricing or other matters; ● general competitive, economic, industry, market, political (including healthcare reform) and regulatory conditions, civil unrest (including any resulting store closures, damage, or loss of inventory), as well as other factors specific to the markets in which we operate; ● the severity and resulting impact of the cough, cold and flu season; ● the impact on retail pharmacy business as pharmacy benefit management (“PBM”) payors incent or mandate movement away from retail pharmacies to PBM mail order pharmacies; ● our ability to achieve the benefits of our efforts to reduce the costs of our generic and other drugs; ● the risk that changes in federal or state laws or regulations, including to those relating to labor or wages, the Health Care Education Affordability Reconciliation Act, the repeal of all or part of the Patient Protection and the Affordable Care Act (or "ACA"), and decisions of the United States Supreme Court regarding those and other matters relevant to the Company or its operations, and any regulations enacted thereunder may occur; ● the impact of the loss of one or more major third party payor contracts and the risk that providers and state contract changes may occur; 3 Table of Contents ● the risk that we may need to take further impairment charges if our future results do not meet our expectations; ● our ability to sell our Centers of Medicare and Medicaid Services (“CMS”) receivables, in whole or in part, which could negatively impact our leverage ratio if we do not consummate a sale; ● our ability to grow prescription count and realize front-end sales growth; ● our ability to achieve cost savings
Recommended publications
  • Come Exhibit with Us
    Store Brands Got The Power Come Exhibit With Us 2011 2010 26.0% 2009 25.0% 2008 23.7% 2007 22.3% 21.2% November 14-16 Chicago Presented by the Private Label Manufacturers Association Store Brands ll across the country, store brands power is driving big increases in store brands sales. A New categories. New merchandising ideas. New package designs. New shelf allocation. Store brands are reaching unheard of levels of consumer popularity and retailer commitment. For manufacturers, store brands power is the power to compete with big national brands in category after category without big advertising budgets and promotion allowances. It’s the power to make a small and medium-size company important to retailers. It’s the power to market your products to millions of consumers. It means new opportunities for your business. Store brands power is growing, too. According to GfK Roper, 57% of all shoppers now say that they purchase store brands frequently, up from 36% ten years ago. Moreover, 9 out of 10 consumers say that store brands are now as good as or better than national brands and one-third of all shoppers expect to buy more store brands in the year ahead. November Got The Power THE SHOW FOR STORE BRANDS MORE THAN PRODUCTS PLMA gives you the chance to show your power. For PLMA’s annual show is more than just products, though. nearly 30 years, PLMA’s Private Label Trade Show has PLMA’s Innovation Hall features the latest software and been the place where retailers and suppliers meet to technology to make business more efficient.
    [Show full text]
  • The Jean Coutu Group (Pjc) Inc
    THE JEAN COUTU GROUP (PJC) INC. ANNUAL INFORMATION FORM Financial year ended May 31, 2002 October 18, 2002 TABLE OF CONTENTS ITEM 1 - INCORPORATION................................................................................................................................... 3 1.1 INCORPORATION OF THE ISSUER ................................................................................................................... 3 1.2 CAPITAL STRUCTURE.................................................................................................................................... 3 1.3 SUBSIDIARIES................................................................................................................................................ 4 ITEM 2 - GENERAL DEVELOPMENT OF THE BUSINESS.............................................................................. 4 2.1 HISTORY AND PROFILE ................................................................................................................................. 4 2.2 PRINCIPAL DEVELOPMENT AND ACQUISITIONS OF THE LAST FIVE YEARS ................................................... 5 ITEM 3 - DESCRIPTION OF ACTIVITIES ........................................................................................................... 6 3.1 FRANCHISING................................................................................................................................................ 6 3.1.1 Franchising Business ....................................................................................................................
    [Show full text]
  • Overview of Ftc Antitrust Actions in Pharmaceutical Services and Products
    OVERVIEW OF FTC ANTITRUST ACTIONS IN PHARMACEUTICAL SERVICES AND PRODUCTS Health Care Division Bureau of Competition Federal Trade Commission Washington D.C. 20580 Markus H. Meier Assistant Director Bradley S. Albert Deputy Assistant Director Saralisa C. Brau Deputy Assistant Director September 2009 TABLE OF CONTENTS Page I. INTRODUCTION. ........................................................... 1 II. CONDUCT INVOLVING PHARMACEUTICAL SERVICES AND PRODUCTS. 3 A. Monopolization. ...................................................... 3 B. Agreements Not to Compete. ............................................ 8 C. Agreements on Price or Price-Related Terms. 14 D. Agreements to Obstruct Innovative Forms of Health Care Delivery or Financing. 20 E. Illegal Tying and Other Arrangements. .................................... 20 III. PHARMACEUTICAL MERGERS. ........................................... 20 A. Horizontal Mergers Between Direct Competitors. 20 B. Potential Competition Mergers. ......................................... 44 C. Innovation Market Mergers. ............................................ 47 D. Vertical Mergers...................................................... 49 IV. INDUSTRY GUIDANCE STATEMENTS...................................... 50 A. Advisory Opinions. ................................................... 50 B. Citizen Petition to the Food and Drug Administration. 51 V. AMICUS BRIEFS. ......................................................... 51 VI. INDICES. ............................................................
    [Show full text]
  • Pharmacies Participating in 90-Day Extended Network
    Ambetter from Peach State Health Plan: Pharmacies Participating in 90-Day Extended Network City Name Address 1 Zip Code Phone 24-Hour Chain Name ABBEVILLE ABBEVILLE DISCOUNT DRUGS 201 W MAIN ST 310011213 229 467-2221 N LEADER DRUG STORES INC ACWORTH CVS PHARMACY 4595 HWY 92 30102 770 529-9712 N CVS PHARMACY INC ACWORTH CVS PHARMACY 3513 BAKER RD STE 500 30101 770 917-0408 N CVS PHARMACY INC ACWORTH DOLLAR PRESCRIPTION SHOP TOO 2151 CEDARCREST RD 30101 770 672-0846 N THIRD PARTY STATION CP ACWORTH ELDERCARE PHARMACY 4769 S MAIN ST 30101 770 974-4277 N MHA LONG TERM CARE NETWORK ACWORTH KROGER PHARMACY 6199 HIGHWAY 92 30102 770 924-9105 N THE KROGER CO ACWORTH KROGER PHARMACY 1720 MARS HILL RD 30101 770 419-5495 N THE KROGER CO ACWORTH KROGER PHARMACY 3330 COBB PARKWAY 30101 770 975-8776 N THE KROGER CO ACWORTH LACEY DRUG COMPANY 4797 S MAIN ST 301015392 770 974-3131 N ELEVATE PROVIDER NETWORK ACWORTH LACEYS LTC PHCY 4469 LEMON ST 30101 678 236-0400 N GERIMED LTC NETWORK INC ACWORTH PUBLIX PHARMACY #0566 1727 MARS HILL RD 30101 770 218-2426 N PUBLIX SUPER MARKETS INC ACWORTH PUBLIX PHARMACY #0593 3507 BAKER ROAD SUITE 300 30101 770 917-0218 N PUBLIX SUPER MARKETS INC ACWORTH PUBLIX PHARMACY #1096 6110 CEDARCREST ROAD NW 30101 678 439-3446 N PUBLIX SUPER MARKETS INC ACWORTH RED CARPET PHARMACY 3450 COBB PKWY NW STE 110 301018351 770 529-9277 N LEADER DRUG STORES INC ACWORTH RITE AID PHARMACY 11732 3245 COBB PARKWAY 30101 770 974-0936 N RITE AID CORPORATION ACWORTH RITE AID PHARMACY 11733 1775 MARS HILL ROAD 30101 770 919-0882 N RITE AID
    [Show full text]
  • Clinique Now More Accessible Than Ever Famous Brand Arriving at Jean Coutu
    Press Release For Immediate Release Clinique now more accessible than ever Famous brand arriving at Jean Coutu Varennes, Quebec, May 12, 2017 – The Jean Coutu Group (PJC) Inc. (the "Corporation" or the "Jean Coutu Group") announces the arrival of the famous Clinique brand in several of its affiliated stores in Quebec and New Brunswick. From the outset, Clinique has set itself apart through products adapted for every skin concern. In order to reach a wider clientele, of both women and men, the products are now available in most areas of the province (see list). As of now, all the products can also be purchased online at cliniqueproducts.jeancoutu.com. "We are pleased to offer Clinique products, previously available only in large centres, over a wider territory. The implementation will be staggered over three years. 54 stores will carry the brand by August 2017," said Christian Comtois, Senior Manager, Cosmetics at Jean Coutu Group. "As the high end skincare brand in Canada, Clinique is pleased to partner with Jean Coutu, the most admired and respected retailer in Quebec. We are convinced that Clinique’s beauty vision, based on simple routines that give astonishing results, is completely in line with Jean Coutu’s customers throughout the province. We look forward to the future and this important association between two iconic brands," said Artur Klepacz, Brand General Manager at Clinique Canada and LAB SERIES Skincare For Men. A wide range of products Jean Coutu will carry the popular skincare lines such as the famous 3-Step system, Acne Solutions products, the men’s line, the Smart franchise, anti-aging skincare and several recent products.
    [Show full text]
  • PRECEDENTIAL UNITED STATES COURT of APPEALS for the THIRD CIRCUIT ___Nos. 14-4202, 14-4203, 14-4204, 14-4205, 14-4206, 14-46
    Case: 14-4203 Document: 003112598145 Page: 1 Date Filed: 04/19/2017 PRECEDENTIAL UNITED STATES COURT OF APPEALS FOR THE THIRD CIRCUIT ______ Nos. 14-4202, 14-4203, 14-4204, 14-4205, 14-4206, 14-4602 & 14-4632 ______ IN RE: LIPITOR ANTITRUST LITIGATION Rite Aid Corporation; Rite Aid Hdqtrs. Corporation; JC (PJC) USA, LLC; Maxi Drug, Inc. d/b/a Brooks Pharmacy; Eckerd Corporation, Appellants in No. 14-4202 Walgreen Company; The Kroger Co.; Safeway, Inc.; Supervalu, Inc.; HEB Grocery Company L.P., Appellants in No. 14-4203 Giant Eagle, Inc., Appellant in No. 14-4204 Meijer, Inc.; Meijer Distribution, Inc., Appellants in No. 14-4205 Rochester Drug Co-Operative, Inc.; Stephen L. LaFrance Pharmacy, Inc. d/b/a SAJ Distributors; Burlington Drug Company, Inc.; Value Drug Company; Professional Drug Company, Inc.; American Sales Company LLC, Appellants in No. 14-4206 Case: 14-4203 Document: 003112598145 Page: 2 Date Filed: 04/19/2017 A.F.L.-A.G.C. Building Trades Welfare Plan; Mayor and City Council of Baltimore, Maryland; New Mexico United Food and Commercial Workers Union’s and Employers’ Health and Welfare Trust Fund; Louisiana Health Service Indemnity Company, d/b/a Blue Cross/Blue Shield of Louisiana; Bakers Local 433 Health Fund; Twin Cities Bakery Workers Health and Welfare Fund; Fraternal Order of Police, Fort Lauderdale Lodge 31, Insurance Trust Fund; International Brotherhood of Electrical Workers Local 98; New York Hotel Trades Counsel & Hotel Association of New York City, Inc., Health Benefits Fund; Edward Czarnecki; Emilie Heinle; Frank Palter; Andrew Livezey; Edward Ellenson; Jean Ellyne Dougan; Nancy Billington, on behalf of themselves and all others similarly situated, Appellants in No.
    [Show full text]
  • Rite Aid-Walgreens Pharmacy (F.D.)
    Rite Aid-Walgreens Pharmacy (F.D.) Columbia, SC CONFIDENTIAL OFFERING MEMORANDUM TABLE OF CONTENTS Investment Overview 03 Executive Summary Tenant Overview 04 Tenant Overview Location Overview 05 Regional Map 06 Local Map 07 Property View Market Overview 08 Market Analysis 09 Demographics Confidentiality Agreement 10 Disclaimer Furman Capital Advisors, LLC 101 E. Washington Street, Suite 400 Greenville, SC 29601 | 864.235.6855 FurmanCapital.com INVESTMENT OVERVIEW Executive Summary PROPERTY SUMMARY FINANCIAL SUMMARY 7900 Garners Ferry Road Address NOI $336,652 Columbia, SC 29209 Total GLA ±13,813 SF Cap Rate 10% Total Land Size ±1.87 AC List Price $3,366,520 Parcel Number R19105-01-01 Construction Steel frame and brick Year Built 2004 Parking Spaces ±64 INVESTMENT STRENGTHS • Walgreen Boots Alliance (S&P: BBB) guarantees the NNN absolute lease through its acquisition of Rite Aid • WBA (NASDAQ: WBA) has a market cap of $118B • 5+ years remain on lease (Feb 2025) • Signalized hard corner intersection has exposure to over 49,000 VPD • Large, squared-off 1.87 acre parcel offers great potential of redevelopment with dual points of egress/ ingress • ±13,800 SF steel frame and brick building with drive-thru • Built in 2004 • Sub-tenant Family Dollar occupied in February ‘19 3. Rite Aid (dark) | Columbia, SC TENANT OVERVIEW Tenant Summary Rite Aid began in 1962 as Thrift D Discount Center, opening its first store in Scranton, Pennsylvania. After several years of growth, Rite Aid adopted its current name and debuted as a public company in 1968. Ten years after its first store opened, Rite Aid operated 267 locations in 10 states.
    [Show full text]
  • CVS Corporation 2004 Annual Report H Cvrs Narrative 3/17/05 12:18 PM Page +6
    h_cvrs_narrative 3/17/05 12:17 PM Page +3 At CVS, it’s all in a day’s work... CVS Corporation 2004 Annual Report h_cvrs_narrative 3/17/05 12:18 PM Page +6 2:00am Another customer finds relief. From a toddler’s ear infection to a flare up of asthma, illnesses often have little regard for the clock. CVS has been doing its part to help, with approximately 60 percent of our stores offering 24- or extended- hour service. It’s just one of the many ways we make our pharmacy experience “CVS easy.”™ After all, the pharmacy accounts for 70 percent of our overall sales. CVS has a 13.5 percent share of the retail pharmacy market nationally, and we fill one in every five prescriptions in markets where we operate. Thanks to the Pharmacy Service Initiative (PSI) we launched in 2003, CVS is also making sure that prescriptions are “ready when promised”™ at any hour. Our pharmacy initiatives have freed up our pharmacists to spend more time counseling customers as well. As a result, customer service scores posted healthy gains in 2004. To realize similar benefits in the acquired Eckerd stores, we completed the training of more than 11,000 pharmacists and pharmacy support personnel on CVS systems, service processes, and standards. With more than 5,300 retail stores throughout the country and more on the way, CVS is well positioned to benefit from long-term pharmacy growth trends. The U.S. population is aging, healthcare costs are rising, and pharmaceuticals remain often the most cost-effective form of treatment.
    [Show full text]
  • Pharmacies Located in North Carolina
    Blue Cross and Blue Shield of North Carolina Limited Network: Pharmacies Located in North Carolina Pharmacy Name Address City State Zip Phone Number 1ST RX PHARMACY 837 N CENTER ST STATESVILLE NC 28677 7048720880 1ST RX PHARMACY INC- GREENBRIAR 308-A MOCKSVILLE HWY STATESVILLE NC 28625 7048786225 A1 PHARMACY AND SURGICAL SUPPLY LLC 124 FOREST HILL RD LEXINGTON NC 27295 3362246500 A2Z HEALTHMART PHARMACY 1408 ARCHDALE DR CHARLOTTE NC 28210 9803550906 ABERDEEN PRESCRIPTION SHOPPE 1389 N SANDHILLS BLVD ABERDEEN NC 28315 9109441313 ADDICTION RECOVERY MEDICAL SERVICES 536 SIGNAL HILL DRIVE EXT STATESVILLE NC 28625 7048181117 ADULT CLINIC AND GERIATRIC CENTER A 25 OFFICE PARK DRIVE JACKSONVILLE NC 28546 9103534878 ADVANCED HOME CARE 4001 PIEDMONT PKWY GREENSBORO NC 27265 3368788950 AKERS PHARMACY INC 1595 E GARRISON BLVD GASTONIA NC 28054 7048653411 ALBEMARLE COMPNDN N PRESCRIPT CNT 944 N FIRST ST ALBEMARLE NC 28001 7049836176 ALBEMARLE PHARMACY 105 YADKIN ST ALBEMARLE NC 28001 7049838222 ALLCARE PHARMACY SERVICES, LLC 5176 NC HIGHWAY 42 W STE H GARNER NC 27529 9199267371 ALLEN DRUG 220 S MAIN ST STANLEY NC 28164 7042634876 ALLEN DRUGS INC 9026 HIGHWAY 17 POLLOCKSVILLE NC 28573 2522245591 ALMANDS DRUG STORE 3621 SUNSET AVE ROCKY MOUNT NC 27804 2524433138 ANDERSON CREEK PHARMACY, INC 6779 OVERHILLS RD SPRING LAKE NC 28390 9104976337 ANGIER DISCOUNT DRUG 253 N RALIEGH STREET ANGIER NC 27501 9196399623 ANSON PHARMACY INC 806 CAMDEN RD WADESBORO NC 28170 7046949358 APEX PHARMACY 904 W WILLIAMS ST APEX NC 27502 9196297146 ARCHDALE DRUG AT CORNERSTONE
    [Show full text]
  • 2017 Annual Report
    2017 ANNUAL REPORT TABLE OF CONTENTS MESSAGE TO SHAREHOLDERS ................................................................................................................................. 2 CORPORATE PROFILE ............................................................................................................................................. 3 MANAGEMENT'S DISCUSSION AND ANALYSIS ........................................................................................................... 8 1. GENERAL INFORMATION ...................................................................................................................... 8 2. DEFINITIONS ....................................................................................................................................... 8 3. SELECTED ANNUAL INFORMATION FOR FISCAL YEARS 2017, 2016 AND 2015 ......................................... 9 4. OPERATING SEGMENTS PERFORMANCE FOR FISCAL YEARS 2017 AND 2016 ........................................ 11 5. QUARTERLY RESULTS ....................................................................................................................... 12 6. INFORMATION ON THE PJC NETWORK OF FRANCHISED STORES ........................................................... 14 7. LIQUIDITY AND CAPITAL RESOURCES .................................................................................................. 15 8. FINANCIAL INSTRUMENTS AND OFF-BALANCE SHEET ARRANGEMENTS .................................................. 18 9. RELATED PARTY TRANSACTIONS
    [Show full text]
  • 1 CANADA (Class Action) SUPERIOR COURT PROVINCE of QUEBEC DISTRICT of MONTREAL M. HÉBER
    1 CANADA (Class Action) SUPERIOR COURT PROVINCE OF QUEBEC ____________________________________ DISTRICT OF MONTREAL M. HÉBERT NO: 500-06-001085-204 Petitioner -vs.- ANGITA PHARMA INC., legal person duly incorporated, having its head office at 504- 1570 rue Ampère, City of Boucherville, Province of Quebec, J4B 5Z5 and THE JEAN COUTU GROUP (PJC) INC., legal person duly incorporated, having its head office at 11011 boul. Maurice-Duplessis, City of Montreal, Province of Quebec, H1C 1V6 Respondents ____________________________________ ____________________________________________________________________ APPLICATION TO AUTHORIZE THE BRINGING OF A CLASS ACTION & TO APPOINT THE PETITIONER AS REPRESENTATIVE (Art. 574 C.C.P. and following) ____________________________________________________________________ TO ONE OF THE HONOURABLE JUSTICE OF THE SUPERIOR COURT, SITTING IN AND FOR THE DISTRICT OF MONTREAL, YOUR PETITIONER STATE AS FOLLOWS: I. GENERAL PRESENTATION A) The Action 1. Petitioner wishes to institute a class action on behalf of the following class, of which she is a member, namely: • All persons who have a pharmacy record that was accessed by Angita Pharma or any other group to be determined by the Court; 2. This is a case of the intentional violation of Class Members’ privacy rights; Respondent Angita Pharma was given access to customers’ confidential pharmacy 2 records for profit. This access was unauthorized and illegal; Respondent Jean Coutu was reckless or grossly negligent for failing to put in place safeguards that would prevent this type of conduct from being able to take place; 3. Over 200 pharmacists (73 of which are affiliated with Jean Coutu) have been accused by their professional order, the Ordre des pharmaciens du Québec, of allowing Respondent Angita Pharma access to their clients’ confidential files; 4.
    [Show full text]
  • Petitoner's Jurisdictional Brief
    IN THE FLORIDA SUPREME COURT S. Ct. Case No.: CASE NO.: 3D05-2253 GARRETT DENT, Petitioner/Plaintiff, vs. DENNIS PHARMACY, INC., Respondent/Defendant. __________________________/ PETITONER’S JURISDICTIONAL BRIEF Respectfully submitted, David S. Wieder, Esq. Fla. Bar No.:153129 David S. Wieder, P.A. Hermelee & Geffin, LLC Counsel for Garrett Dent 25 S.E. 2nd Ave., Suite 1135 Miami, Florida 33131 Telephone: (305) 373-5444 Facsimile: (305) 373-0039 & David Hagen, Esq. Fla. Bar No.: 158143 49 E. Flagler St., PH104 Miami, Florida 33131 Telephone:(305) 373-4200 Facsimile: (305) 403-4900 TABLE OF CONTENTS TABLE OF CONTENTS ii TABLE OF AUTHORITIES iii OTHER AUTHORITIES iv STATEMENT OF THE CASE AND FACTS 1 STATEMENT OF JURISDICTION 2 SUMMARY OF THE ARGUMENT 3 ARGUMENT 4 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER A PHARMACIST HAS A DUTY TO WARN CUSTOMERS OF DANGERS ASSOCIATED WITH A PRESCRIPTION DRUG. 4 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER RELIANCE IS A NECESSARY ELEMENT OF A VOLUNTARY UNDERTAKING CAUSE OF ACTION. 7 THE DISTRICT COURTS ARE IN DIRECT CONFLICT REGARDING WHETHER AN UNIDENTIFIED THIRD PARTY CAN FALL WITHIN A REASONABLE AND FORESEEABLE ZONE OF RISK. 8 THE THIRD DISTRICT COURT EXPRESSLY DECLARED VALID FLA. STAT. §465.003 AND FLA. ADMIN. CODE R. 64B16-27.820. 10 CONCLUSION 10 CERTIFICATE OF TYPE SIZE AND STYLE 11 CERTIFICATE OF SERVICE 12 ii TABLE OF AUTHORITIES Arab Termite and Pest Control v. Jenkins, 409 So. 2d 1039 (Fla. 1982). 2 Cheeks v. Dorsey, 846 So. 2d 1169 (Fla. 4th DCA 2003). 9 Clay Electric v.
    [Show full text]